Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …

Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have
been identified. Whether patients with rheumatic diseases, especially those receiving …

Biologic therapies have revolutionized treatment outcomes for patients with inflammatory
arthritis. However, there remains a concern regarding their safety during conception, …

Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood.
The aim was to examine demographic and clinical factors associated with COVID-19 …

Objective To determine whether the rate of serious infection is higher in anti–tumor necrosis
factor (anti‐TNF)–treated rheumatoid arthritis (RA) patients compared with RA patients …

Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one
anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently …

Background . Anti-tumour necrosis factor-α (TNF-α) therapies represent an important
advancement in therapy for rheumatoid arthritis (RA). However, there remains a proportion of …

Background The risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) is thought
to be increased following anti-tumour necrosis factor (anti-TNF) therapy, with a proposed …

Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and …

Objective Rheumatoid arthritis (RA) is associated with an increased risk of coronary artery
disease, possibly acting via shared mechanisms of inflammation. This study was undertaken …